V23 introduces medication disposal solution
BECKLEY, W.Va. — A West Virginia company has released a medication disposal product designed to allow environmentally safe disposal of unused medicines and render the medicines undesirable to potential drug abusers.
V23, a subsidiary of Vaught, announced the launch of Element MDS. The product consists of a tamper-evident bottle into which unused drugs can be placed and then mixed with a special powder and tap water, which turn them into an undesirable, solid gelatinous substance.
Most of the Element MDS’ marketing so far has focused on hospices, but it sells for $9.99, and a spokesman for the company told Drug Store News that it could potentially be sold in retail pharmacies and used in the home as well.
Cypress launches generic Elestat
MADISON, Miss. — Cypress Pharmaceuticals has launched a generic version of an eye care drug made by Boehringer Ingelheim and marketed by Allergan, the company said.
Cypress announced the launch of epinastine hydrochloride ophthalmic solution 0.05%, a generic version of Elestat; BI owns the trademark to Elestat and licenses rights to the drug to Allergan. Elestat is used to relieve itching of the eyes resulting from allergic conjunctivitis.
Cypress’ approval application for the drug included a paragraph IV certification, a legal assertion that the branded drug’s patents are invalid, unenforceable or won’t be infringed by a generic version.
Mithridion’s PSP treatment granted orphan drug designation
MADISON, Wis. — The Food and Drug Administration has granted orphan drug designation to a treatment made by Mithridion for a rare neurological disorder, Mithridion said Monday.
The FDA gave the designation to MCD-386CR, an investigational drug for progressive supranuclear palsy, or PSP, which recently completed early-stage clinical trials. PSP is a progressive brain disease in which neurons in the regions of the brain that control eye movements, balance, walking, speech and cognition degenerate, leading to slowed thinking and difficulties with reasoning, planning and shifting between tasks.
“Orphan status will help us immeasurably to bring together the resources and support needed to evaluate MCD-386CR in this rare but important disease and indeed other devastating brain diseases for which there are no current therapies,” Mithridion CEO Trevor Twose said. “Based on results in preclinical studies, we believe MCD0386CR potentially will help restore cognition, so vital to human functioning, and potentially could treat the underlying processes causing the degeneration of neurons in PSP.”
The FDA gives orphan drug designation to investigational treatments for diseases that affect fewer than 200,000 people in the United States.